Assessment of some prescribed drugs in the management of COVID-19 on the survival function: A preliminary report from a single center in Iraq

Marwan Salih AL-NIMER 1 *, Talar Ahmad MERZA 2

1 Department of Pharmacology, Faculty of Medicine, Diyala University, Baqubah 32001, Iraq.
2 Department of Clinical Pharmacy, Faculty of Pharmacy, Hawler Medical University, Erbil 44001 Erbil, Iraq.
* Corresponding Author. E-mail: alnimermarwan@gmail.com (M.S.); Tel. +964-790-260 02 91.
Received: 22 May 2021 / Revised: 07 August 2021/ Accepted: 05 September 2021

ABSTRACT: Several medications are used to treat the patients and to control the spread of the disease. Some of these drugs proved to be harmful besides drug-drug interactions can be occurred particularly in old-age groups or patients with chronic diseases. This study aimed to investigate the effects of several drugs on the survival outcome of COVID-19 patients hospitalized in a single medical center in Erbil, Iraq. 204 patients (128 men and 76 women) with COVID-19 were recruited from the West Erbil Emergency hospital between August 10 and November 20, 2020. The primary outcome measures were the survival rate during the course of illness taking into consideration the number and the generic name of prescribed drugs, the percentage of saturated blood oxygen (sPO2), and the age. A total number of sixty-four patients died. Non-survivors are characterized by having a significantly lower percentage of sPO2 and used a significantly high mean value of a number (4-5) of drugs during the course of treatment. The percentage of non-survivors who used fluoroquinolones was significantly higher than the corresponding percentage of survivors (37.5 vs 21.4, p=0.016). The cumulative odds ratio (> 1.0) was observed significantly (χ2= 6.286, p=0.012) in patients who used five-drug items despite the sPO2≥ 90%. We conclude that drug combinations of more than three drugs are harmful in old-age group patients, and dexamethasone, carbapenems, and fluoroquinolones should be not prescribed as empiric therapy.

KEYWORDS: COVID-19; survival; antivirals; dexamethasone; antibiotics.

1. INTRODUCTION

COVID-19 is a pandemic disease caused by a positive-sense single-stranded RNA virus [1,2]. A new strain of coronavirus is the causative agent of COVID-19 which is the outbreak that started in Wuhan-China in December 2019 [3]. COVID-19 is an atypical respiratory disease with multiple complications that progressed to respiratory failure, renal failure, and death. Old-age and obese people, patients with cardiovascular, respiratory, and endocrine diseases are more susceptible to get coronavirus (CoV) infection [4]. Several medications are used to survive the patients and to control the spread of the disease. Anti-viral agents including a combination of lopinavir and ritonavir, remdesivir, favipiravir, arbidol, ribavirin, and so on are used with discrepancy results [5-8]. Dexamethasone as an adjunct medicine to patients receiving respiratory support (oxygen therapy and/or mechanical ventilation) reduced the mortality rate of hospitalized COVID-19 patients [9]. Heparin (an injectable anticoagulant) is indicated in COVID-19 to overcome the coagulation disorder observed with CoV-infection [10]. It has been found that heparin therapy associated with a significantly lower mortality rate in COVID-19 patients when the data were adjusted for many confounding factors e.g. age, sex, hyperpyrexia, low saturated blood oxygen, and using the antivirals [11]. Azithromycin is a macrolide antibiotic with the antiviral property was indicated in the management of COVID-19 [12]. Azithromycin alone or in combination with hydroxychloroquine reduced the hospitalized inpatient mortality rate by 4% and 6.3%, respectively [13]. In addition, varieties of antimicrobials are used as monotherapy or in combination to control the secondary bacterial infections are also prescribed [14]. Some authors believed that fluoroquinolones are useful in the management of CoV-associated pneumonia because fluoroquinolones are indicated to severe community-acquired pneumonia and have multiple immunomodulatory effects characterized by suppressing the pro-inflammatory cytokines [15]. Bacterial co-infections in COVID-19 were
reported without explanation and usually responded to a broad or extended-spectrum of antibiotics [16]. The severity of the COVID-19, the patients using multiple drug therapy, and evidence of concomitant illnesses may collectively affect the mortality rate. Therefore, this study hypothesized that drugs prescribed in the management of the COVID-19 showed different effects on the clinical outcome in hospitalized patients. This cross-sectional observational study aimed to investigate the effects of using several drug modalities on the survival outcome of COVID-19 patients hospitalized in a single medical center in Erbil, Iraq.

2. RESULTS

Table 1 shows that 68.6% of patients were clinically recovered from illnesses, while 31.4% of patients died. There are no significant differences between Group I and II in the gender distribution or the mean of the age. Group I patients was characterized by having a significantly lower percentage of sPO2 and used a significant high mean value of a number of categorized drugs during the course of treatment.

Table 1. Characteristics of the participants.

<table>
<thead>
<tr>
<th>Variables</th>
<th>Group I (non-survived)</th>
<th>Group II (survived)</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number</td>
<td>64 (31.4%)</td>
<td>140 (68.6%)</td>
<td>0.077</td>
</tr>
<tr>
<td>Age (years)</td>
<td>60.9±14.8</td>
<td>57.1±14.0</td>
<td></td>
</tr>
<tr>
<td>Gender (men: women)</td>
<td>45:19</td>
<td>83:57</td>
<td></td>
</tr>
<tr>
<td>sPO2</td>
<td>75.3±12.0</td>
<td>83.9±10.0</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Number of categorized drugs</td>
<td>3.70±0.94 (4.0)</td>
<td>3.33±1.03 (3.0)</td>
<td>0.012</td>
</tr>
</tbody>
</table>

Table 2. Distribution of patients according to the number of prescriptions.

<table>
<thead>
<tr>
<th>Number of drugs</th>
<th>Group I (non-survived)</th>
<th>Group II (survived)</th>
<th>Total</th>
<th>(\chi^2)</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>1 (1.6)</td>
<td>7 (5.0)</td>
<td>8 (3.9)</td>
<td>1.337</td>
<td>0.248</td>
</tr>
<tr>
<td>2</td>
<td>5 (7.8)</td>
<td>18 (12.9)</td>
<td>23 (11.3)</td>
<td>1.134</td>
<td>0.287</td>
</tr>
<tr>
<td>3</td>
<td>19 (29.7)</td>
<td>55 (39.3)</td>
<td>74 (36.3)</td>
<td>0.846</td>
<td>0.358</td>
</tr>
<tr>
<td>4</td>
<td>26 (40.6)</td>
<td>44 (31.4)</td>
<td>70 (34.3)</td>
<td>1.642</td>
<td>0.200</td>
</tr>
<tr>
<td>5</td>
<td>13 (20.3)</td>
<td>14 (10.0)</td>
<td>27 (13.2)</td>
<td>4.039</td>
<td>0.045</td>
</tr>
<tr>
<td>6</td>
<td>0 (0.0)</td>
<td>2 (1.4)</td>
<td>2 (1.0)</td>
<td>0.900</td>
<td>0.343</td>
</tr>
</tbody>
</table>

Table 3. Distribution of patients according to the prescribed drug categories.

<table>
<thead>
<tr>
<th>Variables</th>
<th>Group I (non-survived)</th>
<th>Group II (survived)</th>
<th>Total</th>
<th>(\chi^2)</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Antivirals</td>
<td>23 (35.9)</td>
<td>57 (40.7)</td>
<td>80</td>
<td>0.423</td>
<td>0.516</td>
</tr>
<tr>
<td>Glucocorticosteroids</td>
<td>57 (89.1)</td>
<td>111 (79.3)</td>
<td>168</td>
<td>2.891</td>
<td>0.089</td>
</tr>
<tr>
<td>Anticoagulants</td>
<td>55 (85.9)</td>
<td>119 (85.0)</td>
<td>174</td>
<td>0.028</td>
<td>0.867</td>
</tr>
<tr>
<td>Azithromycin</td>
<td>14 (21.9)</td>
<td>30 (21.4)</td>
<td>44</td>
<td>0.006</td>
<td>0.936</td>
</tr>
<tr>
<td>Fluoroquinolones</td>
<td>24 (37.5)</td>
<td>30 (21.4)</td>
<td>54</td>
<td>5.823</td>
<td>0.016</td>
</tr>
<tr>
<td>Carbenemems</td>
<td>40 (62.5)</td>
<td>70 (50.0)</td>
<td>110</td>
<td>2.749</td>
<td>0.097</td>
</tr>
<tr>
<td>Cephalosporins</td>
<td>21 (32.8)</td>
<td>52 (37.1)</td>
<td>73</td>
<td>0.352</td>
<td>0.553</td>
</tr>
</tbody>
</table>

Figure 1 shows the cumulative odds ratio (> 1.0) was observed significantly (\(\chi^2= 6.258, p=0.011\)) in patients with advanced age who used 3-5 drugs, while the cumulative odds ratio (<1.0) was observed in patients who used 1-2 drugs of whatever age. Figure 2 shows the cumulative odds ratio (> 1.0) was observed significantly (\(\chi^2= 6.286, p=0.012\)) in patients who used 5 drugs despite the sPO2≥ 90%.
3. DISCUSSION

The results of this study indicate that COVID-19 patients with a poor prognostic outcome are presented with significantly low saturated blood oxygen, and who used more frequent medical items, particularly fluoroquinolones. The management of COVID-19 in West Erbil Emergency hospital is usually symptomatic for mild and uncomplicated cases. Antiviral therapy, anticoagulant and dexamethasone are the cornerstone therapy for COVID-19 patients, which supplemented with different antibiotic regimens according to the general health status of the patients. Several studies showed that advanced age is a predictor of the poorly prognostic outcome of COVID-19 patients. The results of this study confirmed previous studies that showed older age associated with an increased-odd (1.1, confidence intervals 1.03-1.17) in-hospital death [17]. The ratio of men: women in Group I is more than the corresponding ratio in Group II patients, which indicates that male sex is associated with in-hospital death [18]. A significant association between mortality and hypoxia can be attributed to the complications of CoV infection, including myocardial injury, cardiac arrhythmias, respiratory
failure, cardiogenic shock, and so on [19]. De Smet et al (2020) found that polypharmacy was not an associated risk factor of in-hospital death, while this study finds that the percentage of non-survived patients are significantly used a higher number of medical items compared with survived patients [20]. The possible explanation of this discrepancy is related to the small sample size (81 patients; 19 non-survivors and 62 survivors), and the polypharmacy was not specified in the De Smet et al study [20]. Moreover, advanced age is a risk factor of death which acts synergistically with an increased number of medical items to increase the in-hospital death as shown in Figure 1. Furthermore, there is no association between hypoxia and the number of prescribed drugs as Figure 2 showed that the cumulative odds were higher in patients who used 4-5 drugs despite the percentage of blood oxygen saturation was of >90%. The possible explanation is due to the drug-drug interaction. Moreover, patients who used six drugs showed a lower percentage of poor outcome, which attributed to the drugs that counteract the complications e.g. using anticoagulants for deep venous thrombosis or using cephalosporins instead of fluoroquinolones. Therefore, scientific prescription of drugs of whatever their number could be helpful in the management of coronavirus infection.

Antivirals e.g. remdesivir improves the clinical symptoms and non-significantly reduces the percentage of un-survivors, which agreed with the Beigel et al study [21] who found that the mortality rate in patients who used remdesivir was 6.7% compared with 11.7% in patients treated with placebo by day 15 of treatment. The percentages of non-survivors are higher in patients treated with systemic glucocorticosteroids, carbapenems, and significantly with fluoroquinolones. Previous studies reported that dexamethasone reduced the mortality rate of severe Covid-illness that required oxygen therapy and/or invasive mechanical ventilation [9] while another study showed dexamethasone prescription is associated with increased mortality [18]. In our study, 82.4% (168 out of 204) of patients received glucocorticosteroids therapy without producing a significant effect on the poor outcome. The current study agreed with Liu et al study [22] who reported that antibiotics (carbapenems and fluoroquinolones) increased the mortality rate and the acute organ injury. This observation necessitates not using carbapenems and fluoroquinolones as empirical therapy for COVID-19 without evidence of bacterial infections. Moreover, carbapenems and fluoroquinolones have toxic effects on blood cells and the heart, respectively [23, 24]. Limitations of the study included a small sample size, patients recruited from single-center, and cardio-metabolic risk factors are not considered.

4. CONCLUSION

This study adds new information that antivirals have limited therapeutic effects while other medicines are harmful and of no benefit in the management of COVID-19. Combinations of 3-5 drugs are harmful in old-age group patients and dexamethasone and antibiotics (carbapenems and fluoroquinolones) should not be prescribed as empiric therapy.

5. PATIENTS AND METHODS

This cross-sectional study is carried at Hawler Medical University and coordinated by The West Erbil Emergency Hospital in the Erbil, Iraq. Patients were recruited from the hospital between August 10 and November 20, 2020. Hospitalized patients with confirmed COVID-19 were included regardless of their clinical features or the percentage of saturated blood oxygen. The diagnosis of COVID-19 was achieved by polymerase chain reaction (PCR) assays on the swabs obtained from the nasopharynx at the time of admission into the hospital. Patients with clinical features of upper respiratory tract infections and negative PCR tests for CoV were excluded from the study. The Ethical and Scientific Board at the Ministry of the Health in the Erbil approved this study, and exempt the need for consent. The patients were randomly recruited from the hospital using a random numbers table according to the number of admission sheet records, regardless of their using the generic drug or the number of drugs. Patients treated with symptomatic medicines, including antipyretics, antitussives, antacids, diuretics, bronchodilators, multivitamins, and nutraceuticals...etc. and allopatic therapy including oxygen, intravenous fluids, and invasive mechanical ventilation were excluded from the analysis. The sample size was calculated using α-coefficient (type II error) = 0.05, β-coefficient (type I error) = 0.2, and power = 85%. A total number of 204 patients (128 men and 76 women) with a median age of 59.5 years were assessed. The percentage of saturated blood oxygen (sPO2) was determined during the course of illness. The primary outcome is the survival function of patients using a drug as monotherapy or in combinations. These medicines are antivirals (favipiravir, remdesivir), glucocorticosteroids (dexamethasone [n=154], methylprednisolone [n=11], hydrocortisone [n=3]), anticoagulants (heparin, low molecular weight heparin), azithromycin, carbapenems (meropenem, imipenem), cephalosporins (ceftriaxone, cefotaxime, cephalixin), and fluoroquinolones (ciprofloxacin, levofloxacin, moxifloxacin). The patients were categorized
according to their clinical outcomes during the study period into Group I (non-survived) and Group II (survived).

5.1. Statistical analysis

The results are expressed as a number, percentage, median, and mean ± SD. The data was analyzed by using IBM SPSS Statistics Software version 24 (IBM Corp, Armonk, NY, USA). Differences between Group I and II were analyzed by Chi-square test for categorized data and independent two-sample two-tailed t-test, the difference between the percentages test. The cumulative odds ratio was calculated using the Kaplan Meier test analyzed by Breslow (Generalized Wilcoxon) test. A p-value of ≤ 0.05 is a significant cutoff level.

Acknowledgements: The authors express their gratitude to the staff of The West Erbil Emergency Hospital for their unlimited cooperation.

Author contributions: Concept: M.S.AN.; Design: M.S.AN; Supervision: M.S.AN., T.A.M; Resources: M.S.AN., T.A.M; Materials: T.A.M; Data collection T.A.M; Analysis and Interpretation: M.S.AN; Literature Search M.S.AN; Writing: M.S.AN; Critical Reviews: M.S.AN., T.A.M.

Conflict of interest statement: The authors declared no conflict of interest in the manuscript.

Ethics committee approval: The Ethical and Scientific Board at the Ministry of the Health in the Erbil approved this study.

REFERENCES


